MedTrace Logo

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

NCT01100684 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 611

Last updated 2013-12-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether asimadoline is safe and effective at treating D-IBS.

Conditions

  • Diarrhea Predominant Irritable Bowel Syndrome

Interventions

DRUG

Asimadoline

0.5 mg Asimadoline BID

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • RTI Health Solutions

    collaborator OTHER

  • Tioga Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Allen Mangel, M.D.Ph.D. · CMO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01100684 on ClinicalTrials.gov